Literature DB >> 10873991

Eye cancer incidence in Singapore.

S B Lee1, K G Au Eong, S M Saw, T K Chan, H P Lee.   

Abstract

AIM: To describe the epidemiological characteristics of patients with primary intraocular, conjunctival, and orbital cancers seen in Singapore from 1968 to 1995.
METHODS: Epidemiological data of all cancers diagnosed in Singapore are collected by the Singapore Cancer Registry. The data of all cases of Singapore residents with eye cancers (ICD-9, site 190) were retrieved for analysis. This includes intraocular, conjunctival, and orbital cancers but excludes cancer of the eyelids.
RESULTS: There were 125 patients of which 67 (53.6%) were male and 58 (46.4%) were female. The average annual age standardised incidences for male and female Singapore residents were 1.89 and 1.81 per million respectively. The most common cancer was retinoblastoma (53.6%), followed by malignant melanoma (19.2%) and squamous cell carcinoma (11.2%). The most common cancer among patients younger than 15 years was retinoblastoma (95.7%) and that for those 15 years and older was malignant melanoma (42.6%). The most common subsite was the retina (53.6%), followed by conjunctiva (12.8%), orbit (8.8%), and lacrimal gland (6.4%).
CONCLUSION: The annual age standardised incidence have been stable for the 28 years studied. Retinoblastoma is much more common than melanoma in Singapore. These expanded epidemiological characteristics serve to provide ophthalmologists and epidemiologists with a foundation to monitor future disease patterns in Singapore and provide a basis for comparison with other selected populations elsewhere.

Entities:  

Mesh:

Year:  2000        PMID: 10873991      PMCID: PMC1723550          DOI: 10.1136/bjo.84.7.767

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

1.  The incidence of retinoblastoma in the United States: 1974 through 1985.

Authors:  A Tamboli; M J Podgor; J W Horm
Journal:  Arch Ophthalmol       Date:  1990-01

2.  Incidence of eyelid cancers in Singapore from 1968 to 1995.

Authors:  S B Lee; S M Saw; K G Au Eong; T K Chan; H P Lee
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

Review 3.  The role of epidemiological investigations in the study of ocular tumors.

Authors:  A B Smith; E A Egan
Journal:  Int Ophthalmol Clin       Date:  1980

4.  Epidemiologic features of cancer of the eye, orbit and related adnexa in Canada.

Authors:  A Ayiomamitis
Journal:  Can J Ophthalmol       Date:  1989-10       Impact factor: 1.882

5.  Tumors of the eye and adnexa in the Sudan.

Authors:  M O Malik; E H El Sheikh
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

Review 6.  Epidemiology of tumors affecting the visual system.

Authors:  E C Marshall
Journal:  Optom Clin       Date:  1993

Review 7.  Epidemiologic aspects of uveal melanoma.

Authors:  K M Egan; J M Seddon; R J Glynn; E S Gragoudas; D M Albert
Journal:  Surv Ophthalmol       Date:  1988 Jan-Feb       Impact factor: 6.048

8.  Risk factors for ocular melanoma: Western Canada Melanoma Study.

Authors:  R P Gallagher; J M Elwood; J Rootman; J J Spinelli; G B Hill; W J Threlfall; J M Birdsell
Journal:  J Natl Cancer Inst       Date:  1985-04       Impact factor: 13.506

9.  Incidence of retinoblastoma in the United States.

Authors:  T W Pendergrass; S Davis
Journal:  Arch Ophthalmol       Date:  1980-07

10.  Sunlight exposure as risk factor for intraocular malignant melanoma.

Authors:  M A Tucker; J A Shields; P Hartge; J Augsburger; R N Hoover; J F Fraumeni
Journal:  N Engl J Med       Date:  1985-09-26       Impact factor: 91.245

View more
  17 in total

1.  Clinico-Pathological Spectrum of Ophthalmic Lesions: An Experience in Tertiary Care Hospital of Central India.

Authors:  Yashita Gupta; Renuka Gahine; Nighat Hussain; Mohd Jafar Memon
Journal:  J Clin Diagn Res       Date:  2017-01-01

2.  Population-based incidence of conjunctival tumours in Olmsted County, Minnesota.

Authors:  Lauren A Dalvin; Diva R Salomão; Sanjay V Patel
Journal:  Br J Ophthalmol       Date:  2018-03-06       Impact factor: 4.638

3.  Expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of MMP (TIMP)-1 in conjunctival melanomas and clinical implications.

Authors:  Hyoung Kyun Kim; Seoung Wan Chae; Kyung In Woo; Yoon-Duck Kim
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

4.  Clinicopathological survey of 23 patients with lacrimal fossa lesions in Hong Kong.

Authors:  Danny Siu-Chun Ng; Edwin Chan; Kin Yau; Clement Wai-Nang Chan
Journal:  Int J Ophthalmol       Date:  2011-06-18       Impact factor: 1.779

5.  Incidence of primary malignant orbital tumours in the Netherlands.

Authors:  J H Koopman; M van der Heiden-van der Loo; M R van Dijk; W R Bijlsma
Journal:  Eye (Lond)       Date:  2011-02-18       Impact factor: 3.775

6.  Epidemiology of Ocular Malignancies Among the Lebanese Population: A 12-Year Review.

Authors:  Dany Akiki; Said El Hage; Jad El Masri; Wassef Chanbour
Journal:  Cureus       Date:  2022-01-25

7.  Conjunctival metastatic adenocarcinoma of unknown origin.

Authors:  He J Li; Konstantinos T Tsaousis; Phillip Hoopes; Nick Mamalis
Journal:  BMJ Case Rep       Date:  2016-05-17

Review 8.  Survey on the management of orbital and intraocular tumors among oculofacial surgeons in the Asia-Pacific region.

Authors:  Priscilla Xinhui Wang; Victor Teck Chang Koh; Katherine Lun; Gangadhara Sundar
Journal:  Int Ophthalmol       Date:  2013-10-02       Impact factor: 2.031

9.  Malignant Eyelid Tumors in India: A Study of 536 Asian Indian Patients.

Authors:  Swathi Kaliki; Nandini Bothra; Kavya Madhuri Bejjanki; Arpita Nayak; George Ramappa; Ashik Mohamed; Tarjani Vivek Dave; Mohammad Javed Ali; Milind N Naik
Journal:  Ocul Oncol Pathol       Date:  2018-09-13

10.  Tumors of the eye and ocular adnexa at the Philippine Eye Research Institute: a 10-year review.

Authors:  Rolando Enrique D Domingo; Lilibeth E Manganip; Rolando M Castro
Journal:  Clin Ophthalmol       Date:  2015-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.